NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Correlation
The correlation between NTLA and BMY is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NTLA vs. BMY - Performance Comparison
Key characteristics
NTLA:
-1.00
BMY:
0.22
NTLA:
-1.81
BMY:
0.56
NTLA:
0.80
BMY:
1.07
NTLA:
-0.73
BMY:
0.14
NTLA:
-1.65
BMY:
0.81
NTLA:
42.35%
BMY:
8.36%
NTLA:
69.74%
BMY:
30.87%
NTLA:
-96.45%
BMY:
-70.62%
NTLA:
-96.12%
BMY:
-32.35%
Fundamentals
NTLA:
$710.13M
BMY:
$100.44B
NTLA:
-$5.25
BMY:
-$4.41
NTLA:
-0.10
BMY:
1.14
NTLA:
12.27
BMY:
2.08
NTLA:
0.81
BMY:
6.23
NTLA:
$28.94M
BMY:
$36.44B
NTLA:
$26.34M
BMY:
$23.27B
NTLA:
-$412.49M
BMY:
$11.69B
Returns By Period
In the year-to-date period, NTLA achieves a -41.17% return, which is significantly lower than BMY's -10.81% return.
NTLA
-41.17%
-28.39%
-66.67%
-68.55%
-13.06%
N/A
BMY
-10.81%
-16.83%
-5.48%
7.31%
-0.44%
0.40%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NTLA vs. BMY — Risk-Adjusted Performance Rank
NTLA
BMY
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.94%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.94% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -96.45%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 28.38% compared to Bristol-Myers Squibb Company (BMY) at 9.99%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities